GET DAILY SIGNALSWhy Is MiMedx Group (MDXG) Stock Down -7.85% Today?
Key Takeaways
- MDXG shares fell 7.85% to $3.64, down from the prior session's close of $3.95.
- The primary catalyst was a third-quarter revenue miss, with sales of $62.28 million falling well short of the roughly $68.7 million Wall Street expected.
- Management also cut full-year 2026 revenue guidance to $250 million–$260 million, down from a prior range of $260 million–$290 million.
- The company's wound care business remained under severe pressure, with revenue plunging roughly 71% following January 2026 Medicare reimbursement changes.
- An analyst price-target reduction from Mizuho compounded the negative sentiment, even as the firm kept an Outperform rating.
- Traders are now watching the pending Sanara MedTech acquisition and upcoming Medicare fee-schedule updates for the next signals.
- For more detail on this stock, explore Price Targets, Earnings, and Forecast data on Tickeron's dedicated pages.
- Discover which strategies are currently outperforming by exploring Trending AI Robots.
Opening Summary
MiMedx Group, Inc. (MDXG), a Georgia-based regenerative medicine company that develops placental-tissue allografts for wound care and surgical applications, saw its shares slide sharply in Thursday's session. The stock fell 7.85% to $3.64, down from a previous close of $3.95. The decline extended a post-earnings selloff sparked by disappointing third-quarter results reported after Tuesday's close and a cut to the company's full-year revenue outlook.
Earnings Miss Drives the Selloff
The immediate trigger for the move was a weaker-than-expected third-quarter report. MDXG posted net sales of $62.28 million, a 45% year-over-year decline that missed analyst expectations of roughly $68.7 million. Non-GAAP earnings came in at a loss of $0.01 per share versus a consensus estimate near breakeven, while the company recorded a GAAP net loss of about $9 million, or $0.06 per share.
The shortfall was concentrated in the company's wound care segment, where revenue dropped approximately 71% to $22 million. The company has been navigating a reset triggered by changes to Medicare reimbursement for skin substitutes that took effect on January 1, 2026, which have reduced both pricing and industry-wide volumes.
Guidance Cut Adds to the Pressure
Compounding the earnings disappointment, management lowered its full-year 2026 revenue outlook to a range of $250 million to $260 million, down from its previous guidance of $260 million to $290 million and below the roughly $267 million consensus estimate. While the company said it expects fourth-quarter adjusted EBITDA to improve sequentially, the reduced top-line forecast reinforced concerns that the wound care recovery is proceeding more slowly than anticipated.
Analyst Price-Target Reduction
Adding to the downward pressure, Mizuho trimmed its price target on MDXG to $7.00 from $8.00, citing weakness in the wound care segment, even as it maintained an Outperform rating. The firm noted that wound care sales came in below expectations as the company continues to adapt following the CMS reimbursement overhaul in ambulatory care settings.
Market Context and Trading Activity
The share decline reflected a continuation of bearish sentiment rather than a single-session shock. Trading volume has remained elevated around the earnings event, and the stock has underperformed broader healthcare benchmarks as investors reassessed the timeline for wound care stabilization. Notably, the move did not reflect a collapse in the company's entire business: surgical revenue grew 9% year over year to $40 million, and gross margin improved roughly 11 percentage points sequentially to about 80%. The company also returned to positive adjusted EBITDA of approximately $2 million, underscoring a mixed fundamental picture beneath the headline miss.
What Comes Next for MDXG
Looking ahead, investors will focus on several key developments. The pending acquisition of Sanara MedTech remains a central theme, though the transaction has been delayed by a second request for information from the Federal Trade Commission, extending the regulatory review period. The company expects the deal, if completed, to shift its revenue mix more decisively toward the surgical market. Additionally, traders are watching the final Medicare fee schedules, typically published in November, for any changes affecting skin-substitute reimbursement. A favorable U.S. District Court ruling on the regulatory classification of AXIOFILL and a $25 million patent license agreement provide positive offsets, but near-term visibility into wound care recovery remains limited.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-powered trading bots that are performing strongly under current market conditions. Tickeron offers hundreds of AI trading bots covering thousands of tickers, each varying by strategy, timeframe, performance metrics, and traded symbols. Only the strongest performers are featured in this section, giving traders a focused view of which automated approaches are currently excelling. Explore the page to see which strategies are leading the market today.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
MDXG's RSI Oscillator recovers from oversold territory
The RSI Oscillator for MDXG moved out of oversold territory on October 28, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 35 similar instances when the indicator left oversold territory. In 28 of the 35 cases the stock moved higher. This puts the odds of a move higher at 80%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The 50-day moving average for MDXG moved above the 200-day moving average on October 06, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +1.80% 3-day Advance, the price is estimated to grow further. Considering data from situations where MDXG advanced for three days, in 192 of 262 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
MDXG may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MDXG as a result. In 84 of 106 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 79%.
The Moving Average Convergence Divergence Histogram (MACD) for MDXG turned negative on September 25, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 37 similar instances when the indicator turned negative. In 26 of the 37 cases the stock turned lower in the days that followed. This puts the odds of success at 70%.
MDXG moved below its 50-day moving average on October 16, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for MDXG crossed bearishly below the 50-day moving average on October 21, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 73%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MDXG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
The Aroon Indicator for MDXG entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 3 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. MDXG’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 88 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.621) is normal, around the industry mean (3.070). MDXG has a moderately high P/E Ratio (77.600) as compared to the industry average of (-1.257). Projected Growth (PEG Ratio) (0.070) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.491) among similar stocks. P/S Ratio (1.985) is also within normal values, averaging (439.237).
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MDXG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of patent protected regenerative biomaterial products and bioimplants
Industry Biotechnology
Advertisement